News

Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...
Clinical Trials Arena4m
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s
Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.
Malay Mail13h
New drug, new hope: Roche tests Trontinemab potential to delay or prevent Alzheimer’s
Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...
Alpha Cognition: Unheralded Canadian Pharma Set To Launch Alzheimer's Drug
Alpha Cognition's ZUNVEYL targets Alzheimer's with improved tolerability over existing galantamine therapies. Read why I rate ...
MedPage Today on MSN14h
Can a Herpes Drug Slow Alzheimer's?
TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...
Health and Me on MSN10h
New Drug Could Stop Alzheimer's In Its Tracks In Just 7 Months
A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.